While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [18F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [18F]FDG PET/CT can provide important prognostic information. In addition, [18F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [18F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [18F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [18F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.
CITATION STYLE
Arnon-Sheleg, E., Win, T., Israel, O., Guralnik, L., Moskovitz, M., & Ben-Haim, S. (2022). Diagnostic applications of nuclear medicine: Lung and mediastinal tumors. In Nuclear Oncology: From Pathophysiology to Clinical Applications (pp. 743–809). Springer International Publishing. https://doi.org/10.1007/978-3-031-05494-5_13
Mendeley helps you to discover research relevant for your work.